Literature DB >> 12533710

Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent.

Una Lazdina1, Mats Alheim1, Jessica Nyström1, Catharina Hultgren1, Gallina Borisova2, Irina Sominskaya2, Paul Pumpens2, Darrell L Peterson3, David R Milich4, Matti Sällberg1.   

Abstract

The hepatitis B virus (HBV) core antigen (HBcAg) has a unique ability to bind a high frequency of naive human and murine B cells. The role of HBcAg-binding naive B cells in the immunogenicity of HBcAg is not clear. The HBcAg-binding properties of naive B cells were characterized using HBcAg particles with mutated spike region (residues 76-85) sequences. Deletion of residues 76-85 (HBcDelta76-85) destroyed naive B cell binding, whereas deletion of residues 79-85 did not. HBcAg particles with an Ile instead of the natural Ala at position 80 did not bind naive B cells, whereas reversion of Ile80-->Ala restored B cell binding. Destroying the B cell-binding ability of HBcAg had a marginal effect on the overall B cell immunogenicity of the different particles, suggesting that they were equally efficient in priming T helper cells. Therefore, the importance of HBcAg-binding B cells is studied with relation to the priming of HBcAg-specific cytotoxic T cells (CTLs). The role of HBcAg-binding B cells in the priming of HBcAg-specific CTLs was evaluated by immunization with endogenous HBcAg (DNA immunization) and exogenous recombinant HBcAg particles. Endogenous HBcAg primed HBcAg-specific CTLs in wild-type and B cell-deficient mice, whereas exogenous HBcAg primed HBcAg-specific CTLs only in wild-type mice. Importantly, HBcDelta76-85 did not prime CTLs despite the presence of B cells. Thus, the ability of exogenous HBcAg particles to prime specific CTLs is B cell dependent, suggesting a possible role for HBcAg-binding B cells in HBV infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12533710     DOI: 10.1099/vir.0.18678-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  23 in total

Review 1.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

2.  Combinatorial approach to hepadnavirus-like particle vaccine design.

Authors:  Jean-Noel Billaud; Darrell Peterson; Margaret Barr; Antony Chen; Matti Sallberg; Fermin Garduno; Phillip Goldstein; Wendy McDowell; Janice Hughes; Joyce Jones; David Milich
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

3.  Interaction of the hepatitis B core antigen and the innate immune system.

Authors:  Byung O Lee; Amy Tucker; Lars Frelin; Matti Sallberg; Joyce Jones; Cory Peters; Janice Hughes; David Whitacre; Bryan Darsow; Darrell L Peterson; David R Milich
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

4.  Non-canonical binding of an antibody resembling a naïve B cell receptor immunoglobulin to hepatitis B virus capsids.

Authors:  Norman R Watts; Giovanni Cardone; Joe G Vethanayagam; Naiqian Cheng; Catharina Hultgren; Stephen J Stahl; Alasdair C Steven; Matti Sällberg; Paul T Wingfield
Journal:  J Mol Biol       Date:  2008-04-09       Impact factor: 5.469

Review 5.  Management of chronic hepatitis B in patients from special populations.

Authors:  Ching-Lung Lai; Man-Fung Yuen
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

6.  Mobilizing monocytes to cross-present circulating viral antigen in chronic infection.

Authors:  Adam J Gehring; Muzlifah Haniffa; Patrick T Kennedy; Zi Zong Ho; Carolina Boni; Amanda Shin; Nasirah Banu; Adeline Chia; Seng Gee Lim; Carlo Ferrari; Florent Ginhoux; Antonio Bertoletti
Journal:  J Clin Invest       Date:  2013-08-01       Impact factor: 14.808

7.  The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy.

Authors:  Xiao-Qin Chen; Jie-Wen Peng; Gui-Nan Lin; Mei Li; Zhong-Jun Xia
Journal:  Med Oncol       Date:  2011-05-10       Impact factor: 3.064

8.  Serum levels of B-cell activating factor in chronic hepatitis B virus infection: association with clinical diseases.

Authors:  Cuiling Yang; Na Li; Yawen Wang; Pingping Zhang; Qianqian Zhu; Fang Li; Qunying Han; Yi Lv; Ling Yu; Ping Wei; Zhengwen Liu
Journal:  J Interferon Cytokine Res       Date:  2014-05-08       Impact factor: 2.607

Review 9.  Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.

Authors:  Man Fai Law; Rita Ho; Carmen K M Cheung; Lydia H P Tam; Karen Ma; Kent C Y So; Bonaventure Ip; Jacqueline So; Jennifer Lai; Joyce Ng; Tommy H C Tam
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

Review 10.  Prevention and management of hepatitis B virus reactivation in cancer patients.

Authors:  Ka-Shing Cheung; Wai-Kay Seto; Ching-Lung Lai; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2016-01-06       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.